Showing results (121-130 of 204) with videos related to
Sort By:
Pageof 21
Journal of the National Comprehensive Cancer Network : JNCCN|October 5, 2016
High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male SexZheng Zhou, Alfred W Rademaker, Leo I Gordon, et al.Plos One|February 4, 2014
Multidimensional single-cell analysis of BCR signaling reveals proximal activation defect as a hallmark of chronic lymphocytic leukemia B cellsM Lia Palomba, Kelly Piersanti, Carly G K Ziegler, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2010
Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphomaCraig H Moskowitz, Heiko Schöder, Julie Teruya-Feldstein, et al.Journal of the National Comprehensive Cancer Network : JNCCN|October 7, 2011
NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectivesAndrew D Zelenetz, Islah Ahmed, Edward Louis Braud, et al.Leukemia & Lymphoma|October 3, 2018
Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER studyJeff P Sharman, Andres Forero-Torres, Luciano J Costa, et al.Hemasphere|August 7, 2024
The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 studyAndrew D Zelenetz, Wojciech Jurczak, Vincent Ribrag, et al.Blood Advances|September 16, 2021
Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: is 4 Gy suitable for curable patients?Brandon S Imber, Karen W Chau, Jasme Lee, et al.Leukemia & Lymphoma|November 17, 2021
Successful implementation of outpatient R ± DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: a single-center experienceTerry K Pak, Brianne N Dixon, Michael J Buege, et al.Blood|July 16, 2016
Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapyVindi Jurinovic, Robert Kridel, Annette M Staiger, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS StudyLaurie H Sehn, Andre Goy, Fritz C Offner, et al.Pageof 21